Monitoring Selected National HIV Prevention and Care Objectives By Using HIV Surveillance Data United States and 6 Dependent Areas, 2019: Appendix

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; OI, opportunistic infection (i.e., AIDS-defining condition); CDC, Centers for Disease Control and Prevention [footnotes only].

Note. Stage of disease at time of HIV diagnosis is based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection. Data are based on residence at time of diagnosis. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Area without laws: New Jersey. Areas with incomplete lab reporting: Pennsylvania (excluding Philadelphia) and Puerto Rico.

^aFirst positive HIV test result is within 6 months after a negative HIV test result. The diagnosis of an AIDS-defining condition or a low CD4 test result before the 6 months have elapsed does not change the stage from stage 0 to stage 3.
^bIncludes persons with no CD4 information.

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, Centers for Disease Control and Prevention [footnotes only].

Note: Data are based on residence at time of diagnosis. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month or ≤3 months after HIV diagnosis. A VL test result of < 200 copies/mL indicates HIV viral suppression. VL test results are within 6 months of diagnosis of HIV infection during 2019. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Area without laws: New Jersey. Areas with incomplete lab reporting: Pennsylvania (excluding Philadelphia) and Puerto Rico.

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, Centers for Disease Control and Prevention [footnotes only].

Note: Data are based on address of residence as of December 31, 2019 (i.e., most recent known address). Data for the year 2019 are preliminary and based on death data received by CDC as of December 2020. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the Centers for Disease Control and Prevention. Area without laws: New Jersey. Areas with incomplete lab reporting: Pennsylvania (excluding Philadelphia) and Puerto Rico.

^a Performed ≥3 months apart during 2019.
^b Data should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2019.

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, Centers for Disease Control and Prevention [footnotes only].

Note: Data are based on address of residence as of December 31, 2019 (i.e., most recent known address). Data for the year 2019 are preliminary and based on death data received by CDC as of December 2020. A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results during 2019. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the Centers for Disease Control and Prevention. Area without laws: New Jersey. Areas with incomplete lab reporting: Pennsylvania (excluding Philadelphia) and Puerto Rico.

^a Data should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2019.

Abbreviations: PrEP, preexpoure prophylaxis; n/a, not available; FDA, Food and Drug Administration [footnotes only]; NHSS, National HIV Surveillance System [footnotes only].

^a Estimated by using data from IQVIA pharmacy database reported through September 2020 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported; therefore, values may not sum to column total.
^b Estimated using 2018 data from National HIV Surveillance System (NHSS), National Health and Nutrition Examination Survey, and U.S. Census Bureau’s American Community Survey (ACS). Data are rounded to the nearest 10. Data for which values are unknown were not reported; therefore, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2017 denominators were used for 2017 PrEP coverage data and 2018 denominators were used for 2018 and 2019 PrEP coverage data.
^c PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.
^d Number of persons with PrEP indications in San Juan Municipio was unavailable in 2017 and 2018 data is used for 2017.